Lv5
1154 积分 2021-12-13 加入
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
4天前
已完结
Current therapeutic landscape and future treatment perspectives of MASH
19天前
已完结
Current therapeutic landscape and future treatment perspectives of MASH
19天前
已关闭
Understanding Ras inhibitor resistance
1个月前
已完结
From RAS inhibitor resistance to rational combination strategies
1个月前
已完结
Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer
1个月前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
1个月前
已完结
Abstract PS7-03: A first-in-human phase 1a/b trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant, allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer and other solid tumors: Results from the PIKASSO-01 study
1个月前
已关闭
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
2个月前
已完结
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression
2个月前
已完结
皖公网安备34019202002308
